These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 32038821)

  • 1. Metabolomics, a New Promising Technology for Toxicological Research.
    Kim KB; Lee BM
    Toxicol Res; 2009 Jun; 25(2):59-69. PubMed ID: 32038821
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NMR Based Metabolomics: An Exquisite and Facile Method for Evaluating Therapeutic Efficacy and Screening Drug Toxicity.
    Guleria A; Kumar A; Kumar U; Raj R; Kumar D
    Curr Top Med Chem; 2018; 18(20):1827-1849. PubMed ID: 30465509
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NMR-based metabolomics applied to ecotoxicology with zebrafish (Danio rerio) as a prominent model for metabolic profiling and biomarker discovery: Overviewing the most recent approaches.
    Porto VA; da Rocha Júnior ER; Ursulino JS; Porto RS; da Silva M; de Jesus LWO; Oliveira JM; Crispim AC; Santos JCC; Aquino TM
    Sci Total Environ; 2023 Apr; 868():161737. PubMed ID: 36693575
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolomic Strategies in Biomarker Research-New Approach for Indirect Identification of Drug Consumption and Sample Manipulation in Clinical and Forensic Toxicology?
    Steuer AE; Brockbals L; Kraemer T
    Front Chem; 2019; 7():319. PubMed ID: 31134189
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GC-MS-based metabolomics reveals mechanism of action for hydrazine induced hepatotoxicity in rats.
    Bando K; Kunimatsu T; Sakai J; Kimura J; Funabashi H; Seki T; Bamba T; Fukusaki E
    J Appl Toxicol; 2011 Aug; 31(6):524-35. PubMed ID: 21154879
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NMR-based metabolomics.
    Reo NV
    Drug Chem Toxicol; 2002 Nov; 25(4):375-82. PubMed ID: 12378948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Applications of liquid chromatography coupled to mass spectrometry-based metabolomics in clinical chemistry and toxicology: A review.
    Roux A; Lison D; Junot C; Heilier JF
    Clin Biochem; 2011 Jan; 44(1):119-35. PubMed ID: 20800591
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Urinary and Plasma Metabolomics Identify the Distinct Metabolic Profile of Disease State in Chronic Mouse Model of Multiple Sclerosis.
    Singh J; Cerghet M; Poisson LM; Datta I; Labuzek K; Suhail H; Rattan R; Giri S
    J Neuroimmune Pharmacol; 2019 Jun; 14(2):241-250. PubMed ID: 30315511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential of metabolomics in preclinical and clinical drug development.
    Kumar B; Prakash A; Ruhela RK; Medhi B
    Pharmacol Rep; 2014 Dec; 66(6):956-63. PubMed ID: 25443721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Application of metabolomics in nanotoxicity].
    Zou XX; Wang HJ; Liu LH; Zhang B
    Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2020 Sep; 38(9):712-717. PubMed ID: 33036542
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolomics analysis for biomarker discovery: advances and challenges.
    Monteiro MS; Carvalho M; Bastos ML; Guedes de Pinho P
    Curr Med Chem; 2013; 20(2):257-71. PubMed ID: 23210853
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolomics and Biomarker Discovery in Traumatic Brain Injury.
    Banoei MM; Casault C; Metwaly SM; Winston BW
    J Neurotrauma; 2018 Aug; 35(16):1831-1848. PubMed ID: 29587568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolomic application in toxicity evaluation and toxicological biomarker identification of natural product.
    Chen DQ; Chen H; Chen L; Tang DD; Miao H; Zhao YY
    Chem Biol Interact; 2016 May; 252():114-30. PubMed ID: 27041073
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The utility of metabolomics in natural product and biomarker characterization.
    Cox DG; Oh J; Keasling A; Colson KL; Hamann MT
    Biochim Biophys Acta; 2014 Dec; 1840(12):3460-3474. PubMed ID: 25151044
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current Trends in Cancer Biomarker Discovery Using Urinary Metabolomics: Achievements and New Challenges.
    Burton C; Ma Y
    Curr Med Chem; 2019; 26(1):5-28. PubMed ID: 28914192
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolomics-based parallel discovery of xenobiotics and induced endogenous metabolic dysregulation in clinical toxicology.
    Chen C; Fan Z; Xu H; Tan X; Zhu M
    Biomed Chromatogr; 2019 Feb; 33(2):e4413. PubMed ID: 30357883
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Approaches in metabolomics for regulatory toxicology applications.
    Olesti E; González-Ruiz V; Wilks MF; Boccard J; Rudaz S
    Analyst; 2021 Mar; 146(6):1820-1834. PubMed ID: 33605958
    [TBL] [Abstract][Full Text] [Related]  

  • 18. UPLC-MS for metabolomics: a giant step forward in support of pharmaceutical research.
    Nassar AF; Wu T; Nassar SF; Wisnewski AV
    Drug Discov Today; 2017 Feb; 22(2):463-470. PubMed ID: 27919805
    [TBL] [Abstract][Full Text] [Related]  

  • 19. UPLC-MS(E) application in disease biomarker discovery: the discoveries in proteomics to metabolomics.
    Zhao YY; Lin RC
    Chem Biol Interact; 2014 May; 215():7-16. PubMed ID: 24631021
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.